Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $14.45B | +5.4% | $2.69B | $0.47 | -9.6% | 75.5% | 29.5% |
| Q4 2025 Dec 2025 | $17.56B | — | $-1.65B | $-0.29 | — | 70.0% | 21.0% |
| Q3 2025 Sep 2025 | $16.65B | — | $3.54B | $0.62 | — | 75.0% | 33.2% |
| Q2 2025 Jun 2025 | $14.65B | — | $2.91B | $0.51 | — | 74.2% | 25.7% |
| Q1 2025 Mar 2025 | $13.72B | — | $2.97B | $0.52 | — | 79.3% | 32.3% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can Pfizer convince Wall Street this CFO change is about continuity, not a deeper warning on execution and growth? Maik Kemper Editor in Chief Dave has been a…
